Clinical trial
An Early Exploratory Clinical Study of the Safety, Tolerability, and Initial Efficacy of JY231 Injection for the Treatment of Refractory Autoimmune Diseases (ADs)
NCT06887985 is registered in ClinicalTrials.gov with He Huang as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Early Exploratory Clinical Study of the Safety, Tolerability, and Initial Efficacy of JY231 Injection for the Treatment of Refractory Autoimmune Diseases (ADs)
- Lead sponsor
- He Huang
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- March 31, 2025
- Completion date
- December 31, 2027
- Enrollment
- 45 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.